Commercial Analytics for Pharma and Life Sciences
Access the right data and analytics for every phase of your pharmaceutical product life cycle
No matter where you are in your product life cycle, Medidata AI Commercial Analytics has the pharma and life sciences data ecosystem expertise to provide the rapid insights needed to keep your business moving forward.
Commercial Analytics and Launch Planning
Help your brand reach peak sales quicker by incorporating advanced analytics and AI and Machine Learning algorithms into your launch planning to support patient finding and adherence.
Data Strategy for Launch Success
The early stages of a commercial launch are fraught with pivotal decisions, often made by lean teams with limited data. Medidata AI Commercial Analytics provides pharma and life sciences customers with the infrastructure and expertise needed to acquire and analyze the right data to answer key questions in the months leading up to a launch.
Data Due Diligence and KPI Design
Select the Right Data Sets to Power Launch Planning and Execution–There are over 50 different commercially available RWD data providers today – all with heterogeneous underlying data and utility to support specific use cases.
RWD Disease Understanding & Prediction
Identify Unmet Patient Needs and Points of Intervention with Advanced Patient Analytics – Primary market research is expensive, slow, and provides a narrow view of the patient landscape. Mapping the flow of “most” patients can lead to missed opportunities.
Commercial Execution Optimization
Understand Market Dynamics, Engagement, and Effectiveness–Traditional drug launch models are becoming less effective and cost efficient. Access restrictions have become increasingly difficult, adding to the already challenging reality that more physicians prefer leveraging digital channels to find information rather than in-person engagement.
PMSA 2023: Tree-based Marketing Mix Models
Marketing mix models are used to assess the impact of multiple promotional channels within a company/brand on ROI. Random Forests, by design are better at handling a large number of features and collinearity, and identify interplay between media channels without having to specify this explicitly. Read more about the advantages of this approach in our poster from the 2023 PMSA Annual Conference.
Real World Impact of Patients with Bipolar Disorder or Schizophrenia who Experience High Frequency (HF) of Agitation Episodes
Agitation is common among patients with bipolar disorder (BPD) or schizophrenia (SCZ), but there is little RWD to characterize. This study aimed to identify and characterize the impact of high frequency agitation on healthcare resource utilization. Read more about the research in our poster from the 2023 AMCP Annual Conference.
Clinical Characteristics of Patients with Agitation Episodes Associated with Bipolar Disorder or Schizophrenia
A systematic review in the UK associated agitation, which is common among patients with bipolar disorder (BPD) and schizophrenia (SCZ), with longer inpatient stays, higher readmission rates, and increased medication consumption. Read more about the research in our poster from the 2023 ISPOR Annual Conference.
Future-proof your clinical trial and enhance your evidence generation activities with Medidata Link, which allows sponsors to collect clinical trial data and link it at the patient level to real world data (RWD).
Connected Patient Platform
Connect the new digital health data ecosystem and enable collaboration and precision in patient care with the Medidata AI Connected Patient Platform.
Commercial Data Solutions
Medidata AI Commercial Data Solutions provides commercial pharmaceutical organizations with the data management and insights needed to maximize brand success.